MediGene
Official site for Medigene. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies..
Launch date
Employees
Market cap
CAD42.4m
Enterprise valuation
CAD25m (Public information from Sep 2024)
Share price
€2.32 MDG1.DE
Company register number HRB 115761 (München)
Planegg Bavaria (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 8.7m | 10.5m | 31.2m | 6.0m | 11.0m | 10.0m | 15.9m |
| % growth | (18 %) | 20 % | 199 % | (81 %) | 82 % | (9 %) | 59 % |
| EBITDA | (21.5m) | (6.5m) | 13.1m | (14.6m) | (12.3m) | (14.4m) | (11.9m) |
| % EBITDA margin | (246 %) | (62 %) | 42 % | (242 %) | (112 %) | (144 %) | (75 %) |
| Profit | (28.9m) | (10.0m) | (8.3m) | (16.2m) | (12.1m) | (14.3m) | (11.8m) |
| % profit margin | (330 %) | (95 %) | (27 %) | (268 %) | (110 %) | (143 %) | (74 %) |
| EV / revenue | 7.0x | 4.9x | 1.6x | 5.3x | 2.7x | 3.0x | 1.9x |
| EV / EBITDA | -2.8x | -8.0x | 3.8x | -2.2x | -2.4x | -2.1x | -2.5x |
| R&D budget | 22.3m | 12.8m | 28.5m | 11.5m | - | - | - |
| R&D % of revenue | 254 % | 122 % | 91 % | 191 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | N/A | IPO | |
* | $20.6m | Post IPO Equity | |
€26.0m | Post IPO Equity | ||
* | N/A | €5.9m | Post IPO Equity |
| Total Funding | - | ||
Related Content
Recent News about MediGene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
